Inference of differentiation time for single cell transcriptomes using cell population reference data

Lung cancer exhibits the world's highest mortality rate among malignant cancers worldwide, thereby presenting a significant global challenge in terms of reducing patient mortality. In the field of oncology, targeted immunotherapy has emerged as a novel therapeutic approach for lung cancer. This study aims to explore potential targets for immunotherapy in lung adenocarcinoma (LUAD) through the analysis of Ferroptosis Index (FPI) and Single Cell RNA-Sequencing (scRNA-seq) data. The findings of this research can potentially offer valuable insights for improving LUAD immunotherapy strategies and informing clinical decision-making. Firstly, the relationship between survival and ferroptosis in LUAD patients was analyzed by FPI. Subsequently, the association between ferroptosis and infiltration and regulation of immune cells was explored by immune infiltration analysis and correlation statistics. Lastly, the relationship between major infiltrating immune cell populations and related pathways and prognosis of LUAD patients was analyzed by GSEA and GSVA. To screen out core genes regulating infiltration of immune cell populations, scRNA-seq data of cancer and para-cancerous tissues of LUAD patients were downloaded, followed by cell clustering analysis, cell identification of core subpopulations, pseudotime analysis, single-cell GSVA and pathway enrichment analysis, and identification and functional analysis of core regulatory genes. Moreover, the expression levels of core functional genes in LUAD tissue microarray were detected by immunohistochemistry, and its relationship with the prognosis of LUAD patients was verified. Finally, we used lentivirus with WDFY4 to transfect LUAD A549 cells. CCK-8, flow cytometry apoptosis detection, Scratch wound healing assay, Transwell migration assay, Xenograft nude mice model, immunohistochemical analysis and other experimental methods were used to explore the biological effects of WDFY4 on LUAD in vitro and in vivo. Survival analysis of FPI values in LUAD patients revealed a positive correlation between smaller FPI values and longer overall survival. Immuno-infiltration analysis and its correlation with FPI values revealed that B cells were most strongly associated with ferroptosis. Ferroptosis of cancer cells could promote infiltration and activation of B cell populations, and LUAD patients with more infiltration of B cell populations had longer long-term survival. scRNA-seq data analysis indicated that the B cell population is one of the major cell populations infiltrated by immune cells in LUAD. During the later phases of B cell differentiation in LUAD, there was a decrease in the expression levels of ACAP1, LINC00926, TLR10, MS4A1, WDFY4, and TRIM22 genes, whereas the expression levels of TMEM59, TP53INP1, and METTL7A genes were elevated. The protein-protein interaction (PPI) network analysis indicated that WDFY4 plays a crucial role in regulating B cell differentiation in LUAD. Immunohistochemical analysis of LUAD tissue microarray revealed a significant downregulation of WDFY4 expression, which was closely related to the occurrence sites of LUAD. Moreover, LUAD patients with a low WDFY4 expression exhibited a poorer prognosis. Additionally, experimental findings demonstrated that the overexpression of WDFY4 could inhibit the proliferation and metastasis of A549 cells while promoting apoptosis. It was also confirmed that WDFY4 could inhibit cancer growth in vivo. The results indicate that promoting infiltration and activation of B cell populations could improve the long-term survival of LUAD patients, thereby offering a potential novel immunotherapeutic approach for LUAD. Besides, the promotion of cancer cell ferroptosis and upregulation of WDFY4 expression have been shown to induce the infiltration and activation of B cell populations. Furthermore, the overexpression of WDFY4 can significantly inhibit the growth of lung adenocarcinoma in vitro and in vivo, highlighting its potential as a target for immunotherapy in LUAD.

Single-cell transcriptome sequencing, often referred to as single-cell RNA sequencing (scRNA-seq), is used to measure gene expression at the single-cell level and provides a higher resolution of cellular differences than bulk RNA-seq. With more detailed and accurate information, scRNA-seq will greatly promote the understanding of cell functions, disease progression, and treatment response. Although the scRNA-seq experimental protocols have been improved very quickly, many challenges in the scRNA-seq data analysis still need to be overcome. In this chapter, we focus on the introduction and discussion of the research status in the field of scRNA-seq data normalization and cluster analysis, which are the two most important challenges in the scRNA-seq data analysis. Particularly, we present a protocol to discover and validate cancer stem cells (CSCs) using scRNA-seq. Suggestions have also been made to help researchers rationally design their scRNA-seq experiments and data analysis in their future studies.

The incidence and mortality rates of lung cancer are exceptionally high. Many patients are diagnosed with early stage lung cancer but experience rapid recurrence post-surgery. Many research studies have shown that the unfavorable prognosis of patients may be associated with micro-metastasis in the lymph nodes. Our research aimed to develop a nomogram to predict the prognosis of lung adenocarcinoma (LUAD). Single-cell RNA sequencing (scRNA-seq) data were analyzed to identify 11 cell clusters. Patterns of incoming and outgoing signals were identified across the entire cell population. A weighted gene co-expression network analysis (WGCNA) was conducted to uncover critical genes in LUAD. The intersecting marker genes were used to construct the prognostic model. scRNA-seq data were analyzed to identify 19 cell clusters. We identified 3,464 marker genes from the scRNA-seq dataset, 1,994 differentially expressed genes from the bulk RNA sequencing (RNA-seq) dataset, and 1,863 genes associated with a key module identified by the WGCNA. After performing the intersection, univariate Cox, and least absolute shrinkage and selection operator analyses, a prognostic model was established based on the expression levels of 13 signature genes. Subsequent functional experiments confirmed the role of selected regulated genes. Through the integration of scRNA-seq data and bulk RNA-seq data, we developed an innovative model to predict the prognosis of patients. The risk score was found to be a significant independent predictor and clinical-pathological features of LUAD.

In this paper, we introduce Gene Knockout Inference (GenKI), a virtual knockout (KO) tool for gene function prediction using single-cell RNA sequencing (scRNA-seq) data in the absence of KO samples when only wild-type (WT) samples are available. Without using any information from real KO samples, GenKI is designed to capture shifting patterns in gene regulation caused by the KO perturbation in an unsupervised manner and provide a robust and scalable framework for gene function studies. To achieve this goal, GenKI adapts a variational graph autoencoder (VGAE) model to learn latent representations of genes and interactions between genes from the input WT scRNA-seq data and a derived single-cell gene regulatory network (scGRN). The virtual KO data is then generated by computationally removing all edges of the KO gene—the gene to be knocked out for functional study—from the scGRN. The differences between WT and virtual KO data are discerned by using their corresponding latent parameters derived from the trained VGAE model. Our simulations show that GenKI accurately approximates the perturbation profiles upon gene KO and outperforms the state-of-the-art under a series of evaluation conditions. Using publicly available scRNA-seq data sets, we demonstrate that GenKI recapitulates discoveries of real-animal KO experiments and accurately predicts cell type-specific functions of KO genes. Thus, GenKI provides an in-silico alternative to KO experiments that may partially replace the need for genetically modified animals or other genetically perturbed systems.

Chemical inhibition of sulfation accelerates neural differentiation of mouse embryonic stem cells and human induced pluripotent stem cells

Background: Cancer stem cells (CSCs) play a key role in tumor initiation, progression, and resistance to conventional therapies. These cells possess the ability to self-renew and differentiate, contributing to tumor heterogeneity and recurrence. Preclinical data indicate that targeting cancer stem cell-specific pathways could lead to more effective treatments and prevent relapse, thereby improving outcomes. However, there is limited clinical data to support this, in part due to the challenges of measuring CSCs in the clinical setting. Single-cell RNA sequencing (scRNAseq) data in combination with stemness gene expression signatures were investigated as a novel approach to detect and assess changes in CSC numbers in response to treatment. Methods: Single-cell RNAseq datasets from two clinical trials were interrogated – OPPORTUNE, a window-of-opportunity trial evaluating anastrozole vs anastrozole plus pictilisib (PI3K inhibitor) in 75 patients with ER+ HER2- early breast cancer, and FELINE, a neoadjuvant trial which compared letrozole plus placebo with letrozole plus ribociclib (CDK4/6 inhibitor) in 120 patients with ER+ HER2- early breast cancer. The primary endpoint for OPPORTUNE was the inhibition of tumor cell proliferation as measured by Ki67. The primary endpoint for FELINE was the rate of preoperative endocrine prognostic index (PEPI) score 0 after neoadjuvant endocrine therapy. Thirty-four patients from the FELINE study had available scRNAseq data for analysis; this number was 62 patients for the OPPORTUNE study. Stemness gene expression signatures with published evidence of selectivity for breast CSCs were identified from the literature and their utility in detecting CSCs compared in the datasets. Subsequently, changes in CSC fraction with treatment was assessed. Results: Eight different stemness gene signatures were identified from the published literature. Among these, four (Kim_myc, benporath_es2, Bhattacharya_hESC, and Shats_consensus) exhibited selective expression in a minority of tumor cells, with the Shats consensus signature demonstrating the highest specificity to tumor cells over non-malignant cells. Utilizing a Gaussian mixture model, we estimated that approximately 4.5% of cells within a tumor are likely stem cells. In the OPPORTUNE study, higher stemness scores were observed in luminal B compared to luminal A tumors, but there was no association with PIK3CA mutation status. Changes to Ki67 were inversely associated with the CSC fraction – tumors with higher stemness scores were less likely to achieve a complete cell cycle arrest versus endocrine-sensitive tumors. Similarly, in the FELINE trial, non-responders in the letrozole arm showed a trend towards elevated stemness scores. Conclusion: The use of stemness gene expression signatures in scRNAseq data is a feasible method to assess changes in putative CSC fraction with treatment in breast cancer. Increased stemness scores were associated with more aggressive subtypes and resistance to treatment. Citation Format: Peter Hall,Alejandro Chibly, Peter Schmid, Sarah E Pinder, Arnie Purushotham, Alastair Thompson, Steven Gendreau. Evaluation of breast cancer stem cell gene expression signatures in single-cell RNA sequencing (scRNAseq) data from the OPPORTUNE and FELINE trials, and the association with treatment resistance [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr PS13-01.

Ischemic stroke (IS) is a leading cause of adult disability worldwide. The inflammatory processes involved are complex, making it challenging to fully understand the pathological mechanisms of IS. Phagocytosis plays an important role in eliminating neurotoxic or damaged neurons resulting from inflammatory responses. This study employed bioinformatics methods to analyze single-cell RNA sequencing (scRNA-seq) data to investigate the cell types and molecular biological processes involved in IS. scRNA-seq data for IS were obtained from the Gene Expression Omnibus (GEO). Following sample screening and reprocessing, 5,582 single cells were identified from healthy controls and patients with IS. Uniform manifold approximation and projection (UMAP) was utilized to further explore the cellular composition in IS. Functional enrichment analysis of differentially expressed genes was conducted to identify transcriptional regulators, whereas cell developmental trajectories were predicted to uncover potential cell fate decisions. iTALK was employed to identify potential ligand-receptor axes within the cell-type immune microenvironment of IS. Based on scRNA-seq data analysis, we identified four cell types and their associated subclusters, along with genes exhibiting significant differential expression within these subclusters. Phagocytosis was significantly enriched in cell types linked to IS, while the differentiation trajectories of subpopulations in IS was different. Additionally, multiple receptor-ligand axes were identified, indicating diverse interactions within the immune microenvironment of IS. This study demonstrated that phagocytosis in IS cell types critically influences disease progression. It also predicted the trajectories of infarct cells. These findings provide valuable insights into the molecular and cellular mechanisms underlying IS and highlight potential pathways for therapeutic intervention.

In a single-cell RNA-seq (scRNA-seq) data set, a high proportion of missing values (or an excessive number of zeroes) are frequently observed. For the related follow-up tasks, such as clustering analysis and differential expression analysis, a data set without missing values is generally required. Many imputation approaches have been proposed for this purpose. Multiple imputation (MI) is a well-established approach to address possible biases in a follow-up analysis result based on one-time imputed data. There is a lack of investigation on this in the analysis of scRNA-seq data. In this study, we have investigated how to efficiently apply the MI approach to the clustering analysis and the differential expression analysis of scRNA-seq data. We proposed an MI procedure for clustering analysis and an MI procedure for differential expression analysis. To demonstrate the improvements achieved by MI in clustering analysis and differential expression analysis of scRNA-seq data, we analyzed three well-known scRNA-seq data sets. scIGANs, an scRNA-seq imputation method based on the generative adversarial networks (GANs), has been recently proposed for scRNA-seq data imputation. Multiple randomly imputed data sets can be conveniently generated by this method. We implemented our MI procedures based on scIGANs. We demonstrated that MI yielded improved performances on the clustering analysis and differential expression analysis results. Our applications to experimental scRNA-seq data illustrated the advantages of MI over one-time imputation of missing values in scRNA-seq data.

BackgroundLiver cancer (LC) is a heterogeneous tumor with unfavorable prognosis. T cells play key roles in tumor surveillance and cancer immunotherapy. The aim of this study is to explore the...

The notable progress in single-cell RNA sequencing (ScRNA-seq) technology is beneficial to accurately discover the heterogeneity and diversity of cells. Clustering is an extremely important step during the ScRNA-seq data analysis. However, it cannot achieve satisfactory performances by directly clustering ScRNA-seq data due to its high dimensionality and noise. To address these issues, we propose a novel ScRNA-seq data representation model, termed Robust Graph regularized Non-Negative Matrix Factorization with Dissimilarity and Similarity constraints (RGNMF-DS), for ScRNA-seq data clustering. To accurately characterize the structure information of the labeled samples and the unlabeled samples, respectively, the proposed RGNMF-DS model adopts a couple of complementary regularizers (i.e., similarity and dissimilar regularizers) to guide matrix decomposition. In addition, we construct a graph regularizer to discover the local geometric structure hidden in ScRNA-seq data. Moreover, we adopt the l2,1-norm to measure the reconstruction error and thereby effectively improve the robustness of the proposed RGNMF-DS model to the noises. Experimental results on several ScRNA-seq datasets have demonstrated that our proposed RGNMF-DS model outperforms other state-of-the-art competitors in clustering.

Single-cell RNA sequencing (scRNA-seq) data are widely used to study cancer cell states and their heterogeneity. However, the tumour microenvironment is usually a mixture of healthy and cancerous cells and it can be difficult to fully separate these two populations based on transcriptomics alone. If available, somatic single-nucleotide variants (SNVs) observed in the scRNA-seq data could be used to identify the cancer population and match that information with the single cells' expression profile. However, calling somatic SNVs in scRNA-seq data is a challenging task, as most variants seen in the short-read data are not somatic, but can instead be germline variants, RNA edits or transcription, sequencing, or processing errors. In addition, only variants present in actively transcribed regions for each individual cell will be seen in the data. To address these challenges, we develop CCLONE (Cancer Cell Labelling On Noisy Expression), an interpretable tool adapted to handle the uncertainty and sparsity of SNVs called from scRNA-seq data. CCLONE jointly identifies cancer clonal populations, and their associated variants. We apply CCLONE on two acute myeloid leukaemia datasets and one lung adenocarcinoma dataset and show that CCLONE captures both genetic clones and somatic events for multiple patients. These results show how CCLONE can be used to gather insight into the course of the disease and the origin of cancer cells in scRNA-seq data. Source code is available at github.com/HaghverdiLab/CCLONE.

In this study, we investigated the impact of Nardosinone, a bioactive component in Nardostachys root, on the proliferation and differentiation of neural stem cells. The neural stem cells were isolated from cerebrums of embryonic day 14 CD1 mice. The proliferation of cells was monitored using the cell counting kit-8 assay, bromodeoxyuridine incorporation and cell cycle analysis. Cell migration and differentiation were investigated with the neurosphere assay and cell specific markers, respectively. The results showed that Nardosinone promotes cells proliferation and increases cells migration distance in a dose-dependent manner. Nardosinone also induces the selective differentiation of neural stem cells to neurons and oligodendrocytes, as indicated by the expression of microtubule-associated protein-2 and myelin basic protein, respectively. Nardosinone also increases the expression of phospho-extracellular signal-regulated kinase and phospho-cAMP response element binding protein during proliferation and differentiation. In conclusion, this study reveals the regulatory effects of Nardosinone on neural stem cells, which may have significant implications for the treatment of brain injury and neurodegenerative diseases.

BackgroundRecent advances in single-cell RNA sequencing (scRNA-seq) technology have enabled the identification of individual cell types, such as epithelial cells, immune cells, and fibroblasts, in tissue samples containing complex cell populations. Cell typing is one of the key challenges in scRNA-seq data analysis that is usually achieved by estimating the expression of cell marker genes. However, there is no standard practice for cell typing, often resulting in variable and inaccurate outcomes.ResultsWe have developed a comprehensive and user-friendly R-based scRNA-seq analysis and cell typing package, scTyper. scTyper also provides a database of cell type markers, scTyper.db, which contains 213 cell marker sets collected from literature. These marker sets include but are not limited to markers for malignant cells, cancer-associated fibroblasts, and tumor-infiltrating T cells. Additionally, scTyper provides three customized methods for estimating cell-type marker expression, including nearest template prediction (NTP), gene set enrichment analysis (GSEA), and average expression values. DNA copy number inference method (inferCNV) has been implemented with an improved modification that can be used for malignant cell typing. The package also supports the data preprocessing pipelines by Cell Ranger from 10X Genomics and the Seurat package. A summary reporting system is also implemented, which may facilitate users to perform reproducible analyses.ConclusionsscTyper provides a comprehensive and user-friendly analysis pipeline for cell typing of scRNA-seq data with a curated cell marker database, scTyper.db.

Cell type identification plays a vital role in single-cell RNA sequencing (scRNA-seq) data analysis. Although many deep embedded methods to cluster scRNA-seq data have been proposed, they still fail in elucidating the intrinsic properties of cells and genes. Here, we present a novel end-to-end deep graph clustering model for single-cell transcriptomics data based on unsupervised Gene-Cell Collective representation learning and Optimal Transport (scGCOT) which integrates both cell and gene correlations. Specifically, scGCOT learns the latent embedding of cells and genes simultaneously and reconstructs the cell graph, the gene graph, and the gene expression count matrix. A zero-inflated negative binomial (ZINB) model is estimated via the reconstructed count matrix to capture the essential properties of scRNA-seq data. By leveraging the optimal transport-based joint representation alignment, scGCOT learns the clustering process and the latent representations through a mutually supervised self optimization strategy. Extensive experiments with 14 competing methods on 15 real scRNA-seq datasets demonstrate the competitive edges of scGCOT.

The stimulation of neural stem cells (NSCs) differentiation into neurons has attracted great attention in management of neurodegenerative disease and traumatic brain injury. It has been reported that selegiline could enhance the morphologic differentiation of embryonic stem cells. Therefore this study aimed to investigate the effects of selegiline on NSCs differentiation with focus on the role of neurotrophic factor gene expression. The NSCs were isolated from lateral ventricle of C57 mice brain. The cells were exposed to selegiline in nano to micromolar concentrations for 24 hr or 72 hr. In order to assay the effect of selegiline on NSCs differentiation into neurons, astrocytes and oligodendrocytes, immunocytochemical techniques were utilized. Samples were exposed to specific antibodies against neurons (β tubulin), astrocytes (GFAP) and oligodendrocytes (OSP). The expression of BDNF, NGF and NT3 genes was investigated using Real-Time PCR. Our findings revealed that selegiline increased NSCs differentiation into neurons at 10(-7) and 10(-8) M and decreased the differentiation into astrocytes at 10(-9), while oligodendrocyte did not significantly change in any of the used concentrations. In addition data analyses showed that selegiline increased BDNF, NGF and NT3 gene expression at 24 hr, but did not change them in the other time of exposure (72 hr) except 10(-7) M concentration of selegiline, which increased NT3 expression. Our results indicate selegiline induced the differentiation of NSCs into neurons and in this context the role of neurotrophic factors is important and should be considered.